the toxic note is the thorn in Hjoe's side. It's really that and because of that our fins are lagging. Well, appears to be lagging. I'm sure they have the acct firm and are getting it completed. It all hinges on that. Everything we are waiting to officially hear is to do with that. Nothing is more attractive then announcing you have paid the loan off, followed by audited fins. that partner/board member prick turned on Hjoe and he's itching to sell out from under them. but he can't because of greed. they no doubt will pay him a premium on the note and then some to get him out of their hair. but will be far less costly then to allow him to convert at the pps premium. I also believe there are certain guidelines and conditions set by the ceo as to what and how and when the note holder will be allowed to convert. one reason why we haven't seen him dump the shares yet.
He will be royally pissed knowing intead of getting a few hundred thousand or what have you for the note could have sold for millions once the audit and revs are announced. LOL.
I believe 2016 WILL be Hjoes year as they reveal the execution of their global marketing plan.
(0)
(0)
Hangover Joe's Holding Corporation (HJOE) Stock Research Links
PodcastOne Introduces Innovative Podcast 'Zero Stars'
Zero Stars marks the 47th addition to PodcastOne’s expansive roster of podcasts in 2024.
PodcastOne Achieves Over 3 Billion Downloads
PodcastOne, a leading podcasting platform, is set to premiere Zero Stars, a fresh comedy podcast on October 21, featuring the unique talents of comedian Bobcat Goldthwait and Academy Award-nominated producer Sean McKittrick. This exci... Continue Reading
Immunome's Groundbreaking Presentation on ADC TherapyToday, Immunome, Inc. (Nasdaq: IMNM) is excited to announce its participation in a prominent oncology symposium where it will showcase the preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC). This innovative therapeutic approach could pave the way for enhanced cancer treatments, leveraging Immunome's expertise in targeted cancer therapies.What is IM-1021?IM-1021 is designed to target the... Continue Reading
Introduction to Helius Medical TechnologiesHelius Medical Technologies, Inc. is a pioneering neurotechnology company focused on developing innovative therapeutic solutions aimed at addressing neurogenic balance and gait disorders. Known for its commitment to enhancing patient outcomes, Helius has made significant strides in the medical device sector by offering cutting-edge neuromodulation technologies.Participation in The ThinkEquity ConferenceOn October 30, 2024, He... Continue Reading
KB Home Unveils Silver Lake Estates in Florida
KB Home (NYSE: KBH), recognized as one of the largest and most trusted homebuilders in the U.S., has proudly announced the grand opening of Silver Lake Estates. This new-home community, situated in a vibrant location, showcases a modern approach to home design that aligns perfectly with contemporary lifestyles.
Exceptional Features of Silver Lake Estates
Silver Lake Estates features innovative homes tailored for today's h... Continue Reading
Alignment Healthcare to Present Third Quarter Financial ResultsIn a significant upcoming event, Alignment Healthcare, Inc. (NASDAQ: ALHC) is set to unveil its financial results for the third quarter of 2024. The presentation will occur on a Tuesday evening after the market closes, specifically on October 29. This moment offers investors and interested stakeholders a clearer understanding of the company's current performance and future outlook.Conference Call InsightsF... Continue Reading
Vertex Pharmaceuticals to Present Breakthrough Phase 3 Data
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is set to unveil its pivotal Phase 3 data on suzetrigine, a groundbreaking investigational oral medication designed to selectively inhibit pain signals for the relief of moderate-to-severe acute pain. This significant presentation will occur at the annual meeting of the American Society of Anesthesiologists (ASA), scheduled for October 18–22, highlighting the company's commi... Continue Reading
SpaceX and NASA Collaboration for Future Missions
NASA has recently confirmed that it will launch its Crew-10 and Crew-11 missions to the International Space Station (ISS) in collaboration with SpaceX in 2025. This significant partnership marks a continuation of NASA's reliance on private aerospace companies to facilitate crewed missions to the ISS, especially following complications with Boeing's Starliner program.
Crew-10 Mission Details
The Crew-10 mission is set ... Continue Reading
Madrigal Pharmaceuticals to Host Webcast for Q3 Financial ReleaseRecently, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced an important event for its shareholders and stakeholders. The company is set to deliver its financial results for the third quarter of 2024 on the last day of October, right before the markets launch into a new trading session.Live Webcast DetailsOn the day of the announcement, Madrigal’s leadership will take center stage at 8 a.m. Eastern... Continue Reading
Ferring Pharmaceuticals Showcases Innovations in Fertility CareFerring Pharmaceuticals is gearing up for an impactful presentation at the upcoming annual conference of the American Society for Reproductive Medicine (ASRM). This year’s event is set to take place over several days, offering a platform for healthcare experts and professionals to delve into the latest advances in reproductive medicine.Ferring's Contribution to Fertility MedicineAt this year's ASRM Congres... Continue Reading
Introduction to FOREWARN's Collaboration with REALTORS®In an exciting development for the real estate industry, FOREWARN, LLC, a pioneering provider of real-time information solutions, has joined forces with the New Hampshire Association of REALTORS (NHAR). This strategic partnership aims to promote the safety and well-being of real estate agents across the state, equipping them with essential tools to mitigate risks and enhance their professional practice.What is FOREWARN?... Continue Reading